TIME has named Sprout Pharmaceuticals among just 10 organizations globally shaping the future of health and life sciences. This recognition follows a defining period of momentum for Sprout and its flagship treatment, Addyi. In December 2025, the...
growing U.S. generics subsidiary of IBSA (Institut Biochimique SA), announced that its Diclofenac Epolamine Topical System 1.3%, the authorized generic of Flector® (diclofenac epolamine) topical system 1.3%, is now available in a 15-count carton....
Infusor for subcutaneous delivery of furosemide meets the General Safety and Performance Requirements (GSPRs) of EU MDR 2017/745. CE Marking is a prerequisite for marketing medical devices within the EU and is recognized in numerous other countries...
of Defense (DoD) and will begin commercial deployment of its FDA-cleared wound treatment, Hemastyl®, starting May 1, 2026. Clinical training across VA and DoD facilities will begin May 1, marking the company's first large-scale entry into...
medicines, along with scientists from the Broad Institute of MIT and Harvard, will present advancements related to TfR1 CapX™. A leading AAV capsid that leverages human transferrin receptor 1 (hTfR1) to enable intravenous delivery to the brain and...
to severely active Crohn's disease (CD). "Crohn's disease is a chronic inflammatory condition that affects an estimated 1 million Americans, and its impact often reaches beyond the gut as its unpredictability can impact daily life and emotional...
allogeneic HSCT face prolonged periods of immunosuppression and routinely require extended antifungal prophylaxis,1 representing a setting where differentiated dosing, improved side effect profile, and reduced DDI is beneficial, and comparable...
T cell (Treg) therapies, today announced the receipt of U.S. Food and Drug Administration (FDA) clearance to initiate CK0801 Phase 2 clinical trial, for the treatment of aplastic anemia. Aplastic anemia, a rare and life-threatening blood disorder,...
Ascletis Pharma Inc. announces completion of enrollment in its 13-week U.S. Phase II study (NCT07321678) evaluating ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist, for the treatment of type 2 diabetes mellitus (T2D). T2D is the...
entitled, "WORMS-Defined Meniscal Pathology is Associated with Femoral Bone-Shape Change, with Attenuation in IA TPX-100 Treated Knees" (Poster #665) at the Osteoarthritis Research Society International (OARSI) 2026 World Congress in West Palm...
and Alzheimer's disease. The tools to visualize them with molecular precision have not existed until now. Over the next 12 months, he plans to validate working prototypes and assemble a team to scale them into essential laboratory tools....
the legs (deep vein thrombosis [DVT]) or lungs (pulmonary embolism [PE]), and reduce the risk of them recurring. For every 100,000 patients treated, Eliquis has resulted in an estimated $3 billion in total healthcare cost savings and avoidance,...
option that advances the standard of care for people living with this complex condition." At Month 24 of the study, 69% (103/149) of participants achieved a physiologic GC dose (≤11 mg/m2/day hydrocortisone equivalents), with many participants...
announced that the U.S. Food and Drug Administration (FDA) approved IDVYNSO™, a new, two-drug single-tablet regimen of 100 mg doravirine and 0.25 mg islatravir, for the treatment of HIV-1 infection in adults to replace the current antiretroviral...
Orthogon Therapeutics announced the closing of a follow-on $11 million financing, bringing its total capital raised to $36 million. This financing supports the continued advancement of its first-in-class drug against BK polyomavirus. BK virus...
stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, please visit www.avantorsciences.com
patient rotation during spine surgery is a time-intensive process that increases physical strain on operating room staff.1 Designed to support safe, quick and easy patient maneuvering during spine surgery, the AAT XR allows surgical teams to rotate...
company, announced eligible patients can now access Foundayo™ (orforglipron) – Eli Lilly Company's newest oral GLP-1 innovation – on the Ro platform, adding to Ro's already comprehensive formulary of FDA-approved GLP-1s. Foundayo™ is a once daily...
from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nintedanib Capsules, 100 mg and 150 mg, the generic equivalent of OFEV® (nintedanib) capsules1. Nintedanib is indicated for the treatment of...
BD a leading global medical technology company, announced the launch of the HemoSphere Stream™ Module, a new innovation which gives clinicians continuous, noninvasive visibility into patients' blood pressure. The module delivers real-time,...
